

3 July 2013

Shin Nippon Biomedical Laboratories, Ltd.

CEO and President, Ryoichi Nagata

Tokyo Stock Exchange, First Section: Code # 2395

Contact Information: CFO and Executive Vice President, Toshihiko Seki

(TEL: +81 (0)3 5565 5001)

Execution of Business Collaboration Agreement with the Retina Institute Japan, K.K.

Supporting the Discovery of Medical Treatment for Age-Related Macular Degeneration with iPS Cells

As of July 3rd, 2013, Shin Nippon Biomedical Laboratories, Ltd. (SNBL) announces the execution of Business Collaboration Agreement with Retina Institute Japan, K.K (RIJ).

1. Basis for Business Collaboration

Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) has entered into Business Collaboration Agreement with Retina Institute Japan, K.K (“RIJ”) to collaborate on discovery of medical treatment of retinal diseases, in the way of regenerative medicine using induced pluripotent stem cell (“iPS cell”). SNBL has reached an agreement with RIJ, where SNBL will exclusively conduct the preclinical study for the safety evaluation of the new treatment. Purpose of this collaboration is to achieve early clinical application of regenerative medicine

2. Contents of Business Collaboration

RIJ is authorized venture company of RIKEN, the Institute of Physical and Chemical Research (“RIKEN”). RIJ aims to develop new treatments for age-related macular degeneration by retinal pigment epithelial cell transplantation, under the license granted from RIKEN to exploit its intellectual property to use iPS for regenerative medicine. Starting with this collaboration, RIJ aims to develop photoreceptor cell transplantation, retinal regeneration medicine, and development of new examination methods in the future and aspires to treat intractable retinal disorders of modern era.

In order to establish the new treatment, iPS derived cells must be transplanted into research animals to examine its safety. SNBL will contribute to development of RIJ’s new treatment by bringing wealth of experience and expertise in the non-clinical field, including research and development, such as regenerative treatment technology and ocular testing methods.

3. Overview of RIJ(As of June 30, 2013)

(1) Company Name	Retina Institute Japan, K.K.
(2) Location	Higashi-ku, Fukuoka City, Fukuoka Prefecture
(3) Name and Title of Representative	President and CEO, Tadanao Kagimoto
(4) Business Description	Research and development in the technological field of cell therapy and regenerative medicine
(5) Capital	951,000,000 Yen
(6) Date of Establishment	February 24, 2011
(7) Number of Outstanding Shares	319,000 Shares
(8) Relationship Between the Parties	
Capital Ties	SNBL owns 3,000 shares of the RIJ (less than 1% of the outstanding shares).
Human Relationship	There is no human relationship between the companies in the agreement. There are also no human relations between the persons involved within two companies in the agreement.
Business Relationship	There is no business relationship between the companies in the agreement. There are also no business relations between the persons involved within two companies in the agreement.
Statuses of Related Parties	RIJ is not a related party of SNBL. Also officials of RIJ are not a related party of SNBL.
(9) Consolidated Financial Condition and Results of the Company for Past 3 Years	
Non-disclosure of information due to the collaboration party being an unlisted company.	

4. Agreement Schedule

Execution Date of Business Collaboration Agreement	July 3, 2013
Start Date of Collaboration	After August, 2013 (Tentative)

5. Future Prospective

Going forward, there will be detailed examination on this collaboration with regards to the future performance and impact to our business. All changes and updates will be disclosed in timely fashion. At the present time, the effect of this matter on the earnings of SNBL's current term is minimal.